Up­dat­ed: FDA ap­proves Sarep­ta’s Duchenne mus­cu­lar dy­s­tro­phy gene ther­a­py via ac­cel­er­at­ed path­way

The FDA grant­ed ac­cel­er­at­ed ap­proval to Sarep­ta Ther­a­peu­tics’ Duchenne mus­cu­lar dy­s­tro­phy gene ther­a­py for boys aged 4 and 5 in a de­ci­sion that al­lows ac­cess …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER